T
Tyra Biosciences
Biotech & Life Sciences · Carlsbad, United States · Founded 2018
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs MoreLess
Tyra Biosciences is a clinical-stage biotechnology company that develops next-generation precision medicines for oncology and genetically defined diseases. The company's proprietary SNAP platform enables the rapid and precise development of therapies that target specific genetic mutations, aiming to overcome drug resistance and improve treatment outcomes. Tyra's pipeline includes TYRA-300, an FGFR3-selective inhibitor for the treatment of achondroplasia and non-muscle invasive bladder cancer, and TYRA-200, an FGFR1/2/3 inhibitor with a focus on intrahepatic cholangiocarcinoma and other solid tumors.
The company's business model revolves around the research, development, and eventual commercialization of its drug candidates. Tyra Biosciences collaborates with academic institutions and other partners to advance its research and clinical trials. The company generates revenue through venture capital funding and public offerings, with future revenue streams expected from drug sales and licensing agreements upon regulatory approval.
Keywords: biotechnology, precision medicine, oncology, FGFR inhibitors, achondroplasia, bladder cancer, cholangiocarcinoma, clinical trials, drug development, genetic diseases
Company overview
Tyra Biosciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- Carlsbad, United States
- Employees
- 100
- Open positions
- 31
- Dealroom signal
- 93.1
Valuation & funding
Tyra Biosciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Feb 2024 | $200M | — | 5AM Ventures · RA Capital Management · OrbiMed · BVF Partners | ↗ |
| IPOOther financing | Sep 2021 | $199M | $626M | Undisclosed | — |
| SERIES BOther financing | Mar 2021 | $106M | $424M | Cormorant Asset Management · Janus Henderson Investors · Tavistock Group · Nextech Invest | — |
| SERIES AOther financing | Jan 2020 | $50M | $200M | Canaan · Alta Partners · Tavistock Group · Boxer Capital | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$177M | — |
| 2025 | $0 | — | −$132M | — |
| 2024 | $0 | — | −$104M | — |
| 2023 | $0 | — | −$80M | — |
| 2022 | $0 | — | −$59M | — |
| 2021 | $0 | — | −$26M | — |
| 2020 | $0 | — | −$9.3M | — |
Growth signals
Tyra Biosciences website traffic
Latest recorded traffic for Tyra Biosciences is 10K monthly website visits, up 0% over the last three months. Tyra Biosciences's team grew 26.6% over the past year.
Hiring
Open positions at Tyra Biosciences
Current openings linked to this company in Dealroom.
Comparisons
Tyra Biosciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Tyra Biosciences's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Tyra Biosciences has talent and traffic
team presence
In the news
Latest news about Tyra Biosciences
Recent press, funding announcements, and product moves mentioning Tyra Biosciences — open to read from the original sources.
Market sentiment
What the market is saying about Tyra Biosciences
An AI-synthesized read of the highest-engagement posts about Tyra Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tyra Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.